Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 5/20 | 0.68 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.68 |
| ▸ | RELA | Q04206 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SCD | O00767 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8122837 | 0.87 | NPC1 (0.70) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL30369583 | 0.82 | LRRK2 (0.81) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL4915099 | 0.81 | NPC1 (1.00) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL16291695 | 0.81 | SCD (0.64) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL30553332 | 0.79 | NPC1 (0.78) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL9893066 | 0.78 | DYRK1A (0.78) | NPC1RAB9AHTTDYRK1ASMN1; SMN2 | |
| SCHEMBL12199347 | 0.78 | HSD17B1 (0.76) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL12199323 | 0.78 | HSD17B1 (0.76) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL5089614 | 0.77 | LRRK2 (0.70) | LRRK2NPC1RAB9AKDM4ENFKB1 | |
| SCHEMBL21568214 | 0.77 | NPC1 (0.71) | LRRK2NPC1RAB9AKDM4ENFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338956-B2 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-04 | — | — | US | disclosed |
| EP-1534275-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014369-A1 | ACYLAMINO-SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388341-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110808-A1 | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals | EDNRA, LIPG, CYP11B1 | LRRK2 3234/4885NPC1 1665/4885RAB9A 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.